198 related articles for article (PubMed ID: 16025321)
21. Activation of nociceptin opioid peptide (NOP) receptor impairs contextual fear learning in mice through glutamatergic mechanisms.
Goeldner C; Reiss D; Wichmann J; Kieffer BL; Ouagazzal AM
Neurobiol Learn Mem; 2009 May; 91(4):393-401. PubMed ID: 19100850
[TBL] [Abstract][Full Text] [Related]
22. The nociceptin/orphanin FQ receptor agonist Ro 64-6198 reduces alcohol self-administration and prevents relapse-like alcohol drinking.
Kuzmin A; Kreek MJ; Bakalkin G; Liljequist S
Neuropsychopharmacology; 2007 Apr; 32(4):902-10. PubMed ID: 16880770
[TBL] [Abstract][Full Text] [Related]
23. Defensive-like behaviors induced by ultrasound: further pharmacological characterization in Lister-hooded rats.
Nicolas LB; Klein S; Prinssen EP
Psychopharmacology (Berl); 2007 Oct; 194(2):243-52. PubMed ID: 17589832
[TBL] [Abstract][Full Text] [Related]
24. A selective small molecule NOP (ORL-1 receptor) partial agonist for the treatment of anxiety.
Ross TM; Battista K; Bignan GC; Brenneman DE; Connolly PJ; Liu J; Middleton SA; Orsini M; Reitz AB; Rosenthal DI; Scott MK; Vaidya AH
Bioorg Med Chem Lett; 2015 Feb; 25(3):602-6. PubMed ID: 25556095
[TBL] [Abstract][Full Text] [Related]
25. The orphanin receptor agonist RO 64-6198 does not induce place conditioning in rats.
Le Pen G; Wichmann J; Moreau JL; Jenck F
Neuroreport; 2002 Mar; 13(4):451-4. PubMed ID: 11930159
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent.
Hirao A; Imai A; Sugie Y; Yamada Y; Hayashi S; Toide K
J Pharmacol Sci; 2008 Mar; 106(3):361-8. PubMed ID: 18319566
[TBL] [Abstract][Full Text] [Related]
27. Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone.
Kuzmin A; Sandin J; Terenius L; Ogren SO
J Pharmacol Exp Ther; 2003 Jan; 304(1):310-8. PubMed ID: 12490606
[TBL] [Abstract][Full Text] [Related]
28. Helix-constrained nociceptin peptides are potent agonists and antagonists of ORL-1 and nociception.
Lohman RJ; Harrison RS; Ruiz-Gómez G; Hoang HN; Shepherd NE; Chow S; Hill TA; Madala PK; Fairlie DP
Vitam Horm; 2015; 97():1-55. PubMed ID: 25677767
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice.
Rupniak NM; Carlson EC; Harrison T; Oates B; Seward E; Owen S; de Felipe C; Hunt S; Wheeldon A
Neuropharmacology; 2000 Jun; 39(8):1413-21. PubMed ID: 10818257
[TBL] [Abstract][Full Text] [Related]
30. Mechanical hyperalgesia in rats with diabetic polyneuropathy is selectively inhibited by local peripheral nociceptin/orphanin FQ receptor and µ-opioid receptor agonism.
Schiene K; Tzschentke TM; Schröder W; Christoph T
Eur J Pharmacol; 2015 May; 754():61-5. PubMed ID: 25697471
[TBL] [Abstract][Full Text] [Related]
31. The endogenous OFQ/N/ORL-1 receptor system regulates the rewarding effects of acute cocaine.
Marquez P; Nguyen AT; Hamid A; Lutfy K
Neuropharmacology; 2008 Mar; 54(3):564-8. PubMed ID: 18082848
[TBL] [Abstract][Full Text] [Related]
32. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
33. The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation.
Paterson NE; Hanania T
Behav Brain Res; 2010 Mar; 208(1):258-64. PubMed ID: 20006648
[TBL] [Abstract][Full Text] [Related]
34. [Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies.
Rizzi D; Rizzi A; Bigoni R; Camarda V; Marzola G; Guerrini R; De Risi C; Regoli D; Calo' G
J Pharmacol Exp Ther; 2002 Jan; 300(1):57-63. PubMed ID: 11752097
[TBL] [Abstract][Full Text] [Related]
35. Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors.
Kuzmin A; Sandin J; Terenius L; Ogren SO
Br J Pharmacol; 2004 Jan; 141(1):132-40. PubMed ID: 14662736
[TBL] [Abstract][Full Text] [Related]
36. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior.
Bleickardt CJ; Mullins DE; Macsweeney CP; Werner BJ; Pond AJ; Guzzi MF; Martin FD; Varty GB; Hodgson RA
Psychopharmacology (Berl); 2009 Mar; 202(4):711-8. PubMed ID: 18923820
[TBL] [Abstract][Full Text] [Related]
38. Mu-opioid receptor knockout mice are more sensitive to chlordiazepoxide-induced anxiolytic behavior.
Wang KC; Lee YJ; Fan LW; Yang PP; Tao PL; Ho IK; Tien LT
Brain Res Bull; 2013 Jan; 90():137-41. PubMed ID: 23142328
[TBL] [Abstract][Full Text] [Related]
39. In vitro characterization of J-113397, a non-peptide nociceptin/orphanin FQ receptor antagonist.
Bigoni R; Calo' G; Rizzi A; Guerrini R; De Risi C; Hashimoto Y; Hashiba E; Lambert DG; Regoli D
Naunyn Schmiedebergs Arch Pharmacol; 2000 May; 361(5):565-8. PubMed ID: 10832612
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological characterization of the nociceptin/orphanin FQ receptor on ethanol-mediated motivational effects in infant and adolescent rats.
Miranda-Morales RS; Pautassi RM
Behav Brain Res; 2016 Feb; 298(Pt A):88-96. PubMed ID: 25907741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
